well known cause of urinary tract infection, and adhesion to the epithelium in the urinary tract seems to be essential in the pathogenesis of urinary tract infections. The blood group antigen P1 is expressed on the epithelium of the urinary tract, and this molecule is assumed to act as a receptor for P fimbriae expressed on P mirabilis.4 These facts led Deighton and colleagues to study the relationship between expression of the P1 antigen and antiproteus titres3 in 140 RA patients and in their 114 healthy siblings. They found that P1 negative RA patients had significantly higher antiproteus titres than the P1 positive patients (p < 0 04).
We have measured the antiproteus titres in 50 RA patients who participated in a controlled clinical trial of fasting and a one year vegetarian diet,5 and in 28 age and sex matched controls by an indirect immunofluorescence technique.6 Antibody titres were expressed in arbitrary units (AU) which were defined as log2 dilution units (1:10 = 1 AU; 1:20 = 2 AU; 1:40 = 3 AU, and so forth). The P blood group status of these patients and controls was also determined by means of a standard microtyping system (DiaMed AG, Murten, Switzerland). All samples were examined under code. In agreement with previous reports, we found that the mean antiproteus titre was significantly higher in the RA patients than in the controls (mean (SD): 3-5 (1-3) AU v 2-2 (0.7) AU; p < 0-0001, Mann-Whitney U test), and that RA patients with a high disease activity (C reactive protein >10 mg/l) had a significantly higher mean titre than patients with low disease activity (mean (SD): [4] [5] [6] (1-3) AU v 30 (1-0) AU; p<0-0001). The mean antiproteus titre was slightly higher in the P1 negative than in the PI positive subjects (mean (SD): 3-5 (1-6) AU v 3-0 (1-3) AU)-RA patients and healthy controls (figure). This difference, however, was not significant (p < 0-27, Mann-Whitney U test). Furthermore, the antiproteus titres did not differ significantly between P1 negative and P1 positive individuals when RA patients and healthy controls were analysed separately (p<0-25 and p<0-14). In the group of RA patients, the P blood group status was not significantly associated with rheumatoid factor status, disease activity, disease duration, or whether or not the patients had a beneficial effect of dietary therapy.
Deighton and colleagues examined a much larger number of patients than we did, and it is possible that the difference between their and our results is attributable to differences in the power of the statistical analyses. However, despite the large number of subjects who were examined, they only found marginally significant differences between P1 negative and P1 positive individuals (p < 0.04). Therefore, we do not believe that the P, antigen plays an important role in the pathogenesis of RA. An 18 year old white male with spastic triplegia secondary to cerebral palsy and a history of multiple corrective orthopaedic procedures developed persistent malaise, followed by an erythematous rash affecting his face and extensor surfaces of the elbows, wrists, knuckles, knees, and feet. On examination, a typical dermatomyositic rash was noted and symmetrical muscular weakness documented in his shoulders, hips, and neck flexors.
Laboratory evaluation revealed a normal peripheral blood count, a sedimentation rate of 13 mm/lst h, borderline positive antinuclear antibody (ANA) at 1:50, negative double stranded (ds)DNA antibodies, and normal muscular enzymes. An electromyogram demonstrated both myopathic and denervation potentials. A muscle biopsy specimen was non-diagnostic and a biopsy specimen of uninvolved skin revealed perivascular lymphocytic infiltrate.
Prednisone (80 mg/day) and hydroxychloroquine (200 mg/day) were prescribed, with excellent clinical response, but the hydroxychloroquine was soon discontinued because of persistent headaches. Attempts to decrease the dose of prednisone over the ensuing weeks were frustrated by worsening of the rash and systemic symptoms. At the seventh month, oral methotrexate (15 mg/ week) was initiated, with virtual resolution of the cutaneous and muscular symptoms over the next four weeks. The dose of prednisone was successfully decreased to nothing over an eight week period.
At 13 months (six months of exposure to methotrexate), the patient was entirely asymptomatic, but a right supraclavicular mass was detected on examination. The pathological report on an excisional biopsy specimen revealed Hodgkin's lymphoma
